Les was diagnosed with GIST more than 20 years ago. After several surgeries, his cancer returned and surgery was no longer an option. Les entered a clinical trial for a targeted therapy and after 14 years on the now-FDA approved drug, he continues to enjoy his grandchildren and fishing. 

DF/BWCC now creates a precise “tumor profile” of genomic changes that helps physicians more accurately diagnose the subtype of a patient’s cancer, predict its behavior and help select precisely targeted therapy

Jeff was diagnosed with advanced lung cancer that had spread to his brain. His tumor tested positive for the ALK gene translocation so his treatment changed from chemotherapy to a targeted therapy that was more effective and had fewer side effects. Four years later, Jeff is still doing well.

Three months after starting a targeted treatment for the EGFR mutation, Ellie’s tumors from lung cancer that had spread to her brain and spine were practically nonexistent. Two and a half years later, she’s still in remission.